Clinical trial NCT02312622: Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Official title: A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Stage IV Non-small Cell Lung Cancer (NSCLC)
Recurrent Non-small Cell Lung Cancer (NSCLC)
Extensive-stage Small Cell Lung Cancer (SCLC)
Recurrent Small Cell Lung Cancer (SCLC)
Tumors Metastatic to Brain
Metastatic Breast Cancer (mBC)
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: Nektar Therapeutics
First posted: 2014-12-09
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description: Primary Objective:

For cohort A and Cohort C, to determine the central nervous system (CNS) disease control rate (number of patients with stable disease or partial response or complete response / total number of treated patients) at 12 weeks following treatment with etirinotecan pegol in patients with advanced non-small cell lung cancer (NSCLC) or with metastatic brain cancer (mBC) with refractory brain metastases

Secondary Objectives:

Cohorts A and C:

* To measure the overall disease control rate and response rate for patients receiving study therapy
* To measure the systemic (non-CNS) disease control rate and response rate for patients receiving study therapy
* To observe the progression free survival of the study population
* To observe the overall survival of the study population

Cohort B:

• To observe CNS and systemic disease control in small cell lung cancer (SCLC)

Cohorts A, B and C:

• To determine the safety profile of etirinotecan pegol

Eligibility criteria: Inclusion Criteria:

* At least 18 years of age.
* Life expectancy of 3 months or longer.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

Advanced or refractory cancer, consisting of

* Metastatic breast cancer (mBC) for which single-agent cytotoxic chemotherapy is indicated. OR
* Histologically-proven metastatic lung cancer:

  * Non-small cell lung cancer (NSCLC) as Stage IV disease or recurrent metastatic disease \[per lung cancer tumor, node and metastasis (TNM) classification system, 7th ed\] (Cohort A) OR
  * Small cell lung cancer (SCLC) as extensive stage or recurrent metastatic disease (cohort B), including tumors with mixed small cell and non-small cell elements.

Prior chemotherapy (at least one of the following):

* At least one line of prior systemic chemotherapy
* At least one line of prior targeted treatment for metastatic disease Adjuvant systemic chemotherapy within prior 6 months Prior treatment for metastatic breast cancer (mBC) must have included taxane-based regimen

Prior chemotherapy, including other investigational therapy, has been completed prior to initiation of study treatment, according to the following:

* ≥ 2 weeks if immediately preceding treatment was chemotherapy/targeted therapy administered on a daily or weekly schedule
* ≥ 3 weeks if immediately preceding treatment was chemotherapy/targeted therapy administered every 2 weeks
* ≥ 4 weeks if immediately preceding treatment was chemotherapy/targeted therapy administered every 3 weeks Previously received at least one CNS directed treatment (such as surgery or radiation) OR not be eligible for CNS stereotactic radiosurgery Measurable CNS disease, either previously untreated (not counting systemic therapy), or progressed following previous radiation treatment. Lesions that have progressed after prior radiosurgery should not be selected as measurable disease if they are suspected of being radionecrosis.

The following measurement criteria are required, as visualized by contrast-enhanced MRI with slice thickness of ≤ 1.5 mm, unless absence of contrast or thicker slices is specifically authorized by Protocol Director. Measurements do not include tumor edema.

* At least one CNS tumor measuring ≥ 10 mm in longest diameter, OR
* At least one CNS tumor measuring 5-9 mm in longest diameter, plus one or two additional CNS tumors measuring ≥ 3 mm in longest diameter, for which the sum of the longest diameters is ≥ 10 mm. Additional tumors are not exclusionary.

Adequate organ function as evidenced by:

* Absolute neutrophil count (ANC) ≥ 1.5 x 10e9/L without G-CSF (filgrastim, pegfilgrastim, or equivalent) support within 7 days
* Hemoglobin (Hgb) ≥ 9.0 g/dL (90 g/L) without blood transfusion within 7 days
* Platelet count ≥ 100 x 10e9/L without platelet transfusion within 7 days
* Bilirubin ≤ 1.5 X upper limit of normal (ULN), except for patients with documented history of Gilbert's disease who may have DIRECT bilirubin ≤ 1.5 X ULN
* Alanine aminotransferase (ALT) ≤ 2.5 X ULN, except ≤ 5 X ULN for patients with liver metastases
* Aspartate aminotransferase (AST) ≤ 2.5 X ULN, except ≤ 5 X ULN for patients with liver metastases
* Serum creatinine ≤ 1.5 X ULN; or calculated creatinine clearance ≥ 50 mL/min (using Cockcroft-Gault formula), or measured creatinine clearance ≥ 50 mL/min.

Exclusion Criteria:

* Previous treatment with a camptothecin derivative (eg, irinotecan, topotecan, and investigational agents including but not limited to exatecan, rubitecan, gimatecan, karenitecin, SN38 investigational agents, EZN 2208, SN 2310, and AR 67) is not allowed
* Patients may not have a known history of leptomeningeal disease, as diagnosed by positive CSF cytology, unless prospective permission for enrollment is granted from the sponsor and the PI
* Patients may not have had major surgery or radiotherapy (therapeutic and/or palliative) within 14 days prior to initiation of study treatment, including CNS-directed radiation therapy. Minor procedures, such as tumor biopsy, thoracentesis, or intravenous catheter placement are allowed with no waiting period
* Patients may not have the following co morbid disease or concurrent illness:

  * Chronic or acute gastrointestinal (GI) disorders resulting in diarrhea of any severity grade; patients may not use chronic anti-diarrheal supportive care (more than 3 days/week) to control diarrhea in the 28 days prior to first dose of investigational drug. (exception: anti-diarrheal medications used to control symptoms from a medication that will be discontinued prior to study are allowed with a 7 day washout before study therapy, for example loperamide for erlotinib-associated diarrhea)
  * Known cirrhosis, defined as Child Pugh class A or higher liver disease
  * Other active malignancy, except for non melanoma skin cancer and carcinoma in situ (of the cervix or bladder)
  * Any other severe/uncontrolled inter current illness or significant co morbid conditions that in the opinion of the investigator would impair study participation or cooperation
* Patients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitors
* Patients may not be receiving the following medications at the time of first dose of investigational drug:

  * Pharmacotherapy for known hepatitis B or C, tuberculosis, or human immunodeficiency virus (HIV)
  * Any of the following enzyme inducing anti epileptic medications (EIAEDs): phenytoin, carbamazepine, oxcarbazepine, phenobarbital
  * Other chemotherapy, hormonal therapy, immunotherapy, other investigational agents, or biologic agents for the treatment of cancer except for bisphosphonates or denosumab
* Pregnant or nursing patients will be excluded from the study

Primary outcomes:
measure: Central Nervous System (CNS) Disease Control Rate (Cohort A and C)
timeFrame: At 12 weeks
Secondary outcomes:
measure: Overall Disease Control Rate (Cohort A and C)
timeFrame: At 12 weeks
measure: Overall Response Rate (Cohort A and C)
timeFrame: At 12 weeks
measure: Systemic (Non-CNS) Disease Control Rate (Cohort A and C)
timeFrame: At 12 weeks
measure: Systemic (Non-CNS) Response Rate (Cohort A and C)
timeFrame: At 12 weeks
measure: Progression-free Survival (PFS) (Cohort A and C)
timeFrame: Date of first dose of pegylated irinotecan NKTR 102 to date of disease progression, assessed up to 2 years
measure: Overall Survival (Cohort A and C)
timeFrame: 4 years
measure: Central Nervous System (CNS) Disease Control (Cohort B)
timeFrame: At 12 weeks
measure: Systemic Disease Control (Cohort B)
timeFrame: At 12 weeks
measure: Related Adverse Events (Toxicity)
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University, School of Medicine
state: California
Study officials:
affiliation: Stanford University Hospitals and Clinics
name: Joel Neal
role: PRINCIPAL_INVESTIGATOR
References: